Additional Chalcogen Attached Directly Or Indirectly To The Diazine Ring By Nonionic Bonding Patents (Class 544/318)
-
Patent number: 8501942Abstract: A monomer of formula (1) is provided wherein R1 is hydrogen or a monovalent C1-C6 hydrocarbon group, and R2 is a group having polymerization functionality. Using the monomer, crosslinking units can be incorporated into a polymer chain. A chemically amplified negative resist composition comprising a base polymer having crosslinking units incorporated therein has a high sensitivity and forms a resist pattern with minimized LER.Type: GrantFiled: July 26, 2011Date of Patent: August 6, 2013Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Daisuke Domon, Satoshi Watanabe
-
Patent number: 8486951Abstract: Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilia syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-? kinase, PDGFR-? kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.Type: GrantFiled: August 21, 2012Date of Patent: July 16, 2013Assignee: Deciphera Pharmaceuticals, LLCInventors: Daniel L. Flynn, Peter A. Petillo, Michael D. Kaufman
-
Patent number: 8475888Abstract: Provided is a liquid crystal compound having general physical properties necessary for a compound, stability to heat, light or the like, a wide liquid crystal phase temperature range, a high clearing point, an excellent compatibility with other liquid crystal compounds, a large refractive index anisotropy and a large dielectric anisotropy. Provided are a liquid crystal composition including the liquid crystal compound, and a liquid crystal display device containing the liquid crystal composition. The compound is represented by formula (1): wherein, for example, R1 is alkyl having 1 to 20 carbons; at least one of the rings A1 to A6 is pyrimidine-2,5-diyl or pyridine-2,5-diyl and the others are 1,4-cyclohexylene or 1,4-phenylene; Z1 to Z6 are a single bond; L1 to L4 is hydrogen or halogen; X1 is hydrogen, halogen, —C?N or alkyl having 1 to 10 carbons; and l, m, n, o, p and q are 0 or 1 and l+m+n+o+p+q=3.Type: GrantFiled: October 14, 2009Date of Patent: July 2, 2013Assignees: JNC Corporation, JNC Petrochemical CorporationInventors: Hiroyuki Tanaka, Kouki Sagou
-
Patent number: 8431716Abstract: The invention relates to special (methyl)acrylaic monomers and concerns more particularly an enhanced process for preparing solutions of alkylimiozolidone (meth)acrylates in water solutions of alkylimidazolidone (meth)acrylates in a light (meth)acrylate.Type: GrantFiled: April 8, 2009Date of Patent: April 30, 2013Assignee: Arkema FranceInventors: Alain Riondel, Jean-Michel Paul
-
Patent number: 8410116Abstract: Disclosed are bis(styryl)pyrimidine or bis(styryl)benzene compounds, represented by Chemical Formula 1, pharmaceutically acceptable salts, a method for preparing the same, and a pharmaceutical composition for the prevention and treatment of amyloidosis-associated diseases, comprising the same as an active ingredient. Having the ability to inhibit the deposition of beta amyloid and to reduce the toxicity of beta amyloid, the derivatives can improve learning and memory and can be useful in the prevention and treatment of amyloidosis-associated diseases. (wherein R1, R2, R3 and X are as defined in the specification).Type: GrantFiled: April 24, 2009Date of Patent: April 2, 2013Assignee: Korea Institute of Science and TechnologyInventors: Kye Jung Shin, Eun Joo Roh, Yun Suk Lee
-
Publication number: 20130066069Abstract: The present invention provides a facile process for the preparation of tri- and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions.Type: ApplicationFiled: August 15, 2012Publication date: March 14, 2013Applicant: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, Francesca Mazzei, David Kay, Andrew Miller
-
Patent number: 8394789Abstract: The invention relates to 5,6-dihydropyrrolo[2,1-?]isoquinoline and pyrrolo[2,1-?]isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.Type: GrantFiled: February 6, 2009Date of Patent: March 12, 2013Assignee: MSD Oss B.V.Inventors: Rachel Deborah van Rijn, Hubert Jan Josef Loozen, Cornelis Marius Timmers, Lars Anders van der Veen, Willem Frederik Johan Karstens
-
Publication number: 20130060031Abstract: The present invention relates to an improved and novel process for the preparation of highly pure (>99.8%) (+)-2(S)-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid (Ambrisentan) of formula (I).Type: ApplicationFiled: March 15, 2010Publication date: March 7, 2013Applicant: Natco Pharma LimitedInventors: Amala Kompella, Kali Satya Bhujanga Ra Adibhatla, Veera Swamy Balina, Srinivasu Kasa, Venkaiah Chowdary Nannapaneni
-
Patent number: 8357684Abstract: Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.Type: GrantFiled: March 2, 2011Date of Patent: January 22, 2013Assignee: Janssen Pharmaceutica NVInventors: Genesis M. Bacani, Eugene Y. Cheung, Christa C. Chrovian, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Alejandro Santillán, Jr., Kathleen Sappey, Kia Sepassi, Virginia M. Tanis, Alvah T. Wickboldt, John J. M. Wiener
-
Publication number: 20130005719Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.Type: ApplicationFiled: June 19, 2012Publication date: January 3, 2013Applicant: Viamet Pharmaceuticals, Inc.Inventors: William J. Hoekstra, Stephen W. Rafferty, Christopher M. Yates, Robert J. Schotzinger, Michael R. Loso, Michael T. Sullenberger, Gary D. Gustafson
-
Publication number: 20130005752Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.Type: ApplicationFiled: June 19, 2012Publication date: January 3, 2013Applicant: Viamet Pharmaceuticals, Inc.Inventors: William J. Hoekstra, Christopher M. Yates, Robert J. Schotzinger, Michael R. Loso, Zachary A. Buchan, Michael T. Sullenberger
-
Publication number: 20120316182Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: June 8, 2012Publication date: December 13, 2012Applicant: CalciMedica, Inc.Inventors: Jeffrey P. WHITTEN, Jonathan Grey, Jianguo Cao, Zhijun Wang, Evan Rogers
-
Publication number: 20120316340Abstract: The use of metal-accumulating plants for implementing chemical reactions.Type: ApplicationFiled: November 18, 2010Publication date: December 13, 2012Applicants: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Claude Grison, Jose Escarre
-
Publication number: 20120309705Abstract: The present invention includes novel 3?-deoxy-3?-methylidene-?-L-nucleosides, pharmaceutical composition comprising such compounds, as well as the methods to treat or to prevent viral infections and in particular HBV and/or HIV infections.Type: ApplicationFiled: December 14, 2010Publication date: December 6, 2012Applicant: NOVADEX PHARMACEUTICALS ABInventors: Xiao Xiong Zhou, Staffan Torssell, Olov Wallner, Piaoyang Sun
-
Publication number: 20120308587Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R4, and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: May 18, 2012Publication date: December 6, 2012Applicant: THERAVANCE, INC.Inventors: Roland Gendron, Adam D. Hughes
-
Publication number: 20120309777Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R7, R6, R7, R8, R9, A, X and Y as defined herein are provided as useful for the treatment of cancer or for the manufacture of anti-cancer agents.Type: ApplicationFiled: February 16, 2011Publication date: December 6, 2012Applicant: UNIVERSITE LAVALInventors: René C. Gaudreault, Sébastien Fortin
-
Patent number: 8324231Abstract: A compound having Formula I: or a pharmaceutically acceptable salt thereof, wherein X, R, R and R are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. The compounds of Formula I are inhibitors of Casein kinase II (CK2) pathways.Type: GrantFiled: April 24, 2008Date of Patent: December 4, 2012Assignee: Exelixis, Inc.Inventors: Elena S. Koltun, Patrick Kearney, Naing Aay, Arlyn Arcalas, Wai Ki Vicky Chan, Jeffry Kimo Curtis, Hongwang Du, Ping Huang, Brian Kane, Moon Hwan Kim, Michael Pack, Amy L. Tsuhako, Wei Xu, Cristiana A. Zaharia, Peiwen Zhou
-
Patent number: 8314087Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: February 15, 2008Date of Patent: November 20, 2012Assignee: Amgen Inc.Inventors: Brian K. Albrecht, Steven Bellon, Shon Booker, Alan C. Cheng, Derin D'Amico, Noel D'Angelo, Jean-Christophe Harmange, Tae-Seong Kim, Longbin Liu, Mark H. Norman, Aaron C. Siegmund, Markian Stec, Ning Xi, Kevin Yang
-
Publication number: 20120277432Abstract: A 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound of the formula (3): [R is a hydrocarbyl group], is prepared by the steps of: (I) reacting an isobutyrylacetate ester with 4-fluorobenzaldehyde and urea in the presence of a protonic compound and a metal salt; (II) oxidizing the reaction product of the step (I); (III) reacting the oxidation product of the step (II) with an organic sulfonyl halide or an organic sulfonyl anhydride; and (IV) reacting the reaction product of the step (III) with N-methyl-N-methanesulfonamide.Type: ApplicationFiled: June 14, 2012Publication date: November 1, 2012Applicant: ASTRAZENECA UK LTD.Inventors: Akio Matsushita, Mizuho Oda, Yasuhiro Kawachi, Jun-ichi Chika
-
Publication number: 20120270877Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.Type: ApplicationFiled: November 1, 2010Publication date: October 25, 2012Applicant: MannKind CorporationInventors: Qingping Zeng, Warren S. Wade, John Bruce Patterson
-
Publication number: 20120213806Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
-
Publication number: 20120213807Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Cameron Smith
-
Publication number: 20120207679Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Applicant: ASTRAZENECA ABInventors: Ylva Gravenfors, Catrin Jonasson, Jonas Malmström, Gunnar Nordvall, David Pyring, Can Slivo, Daniel Sohn, Peter Ström, David Wensbo
-
Publication number: 20120184573Abstract: The invention relates to improved processes for the preparation of ambrisentan. The invention also relates to a novel intermediate useful in the preparation of ambrisentan and a process for the preparation of the intermediate. The invention also relates to new polymorphic form of ambrisentan. In particular, it relates to a polymorphic form, designated as Form I of ambrisentan and a process for the preparation of the Form I.Type: ApplicationFiled: July 12, 2010Publication date: July 19, 2012Inventors: Kaushik Babubhai Sata, Bipin Pandey
-
Patent number: 8217155Abstract: The invention relates to derivatives and metabolites of ambrisentan, including compounds of general Formula (I) or salts, hydrates, solvates, racemates, or optical isomers thereof, wherein R1 is —OH or —OCH3; R2 is —H, lower alkyl (e.g. C1-C4 alkyl) or glycosidyl; and R3 and R4 are independently —CH3, —C(O)H or —CH2OR6, wherein R6 is —H or a hydrocarbyl group having 1 to 20 carbon atoms.Type: GrantFiled: July 31, 2008Date of Patent: July 10, 2012Assignees: Gilead Colorado, Inc., Abbott GmbH & Co. KGInventors: Lawrence S. Melvin, Jr., Martina Ullrich, Hans-Guenther Hege, Jürgen Weymann
-
Patent number: 8217063Abstract: The present application relates to novel lactam-substituted dicarboxylic acid derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.Type: GrantFiled: March 15, 2008Date of Patent: July 10, 2012Assignee: Bayer Intellectual Property GmbHInventors: Michael Hahn, Eva-Maria Becker, Andreas Knorr, Dirk Schneider, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Dieter Lang
-
Publication number: 20120157431Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.Type: ApplicationFiled: December 23, 2011Publication date: June 21, 2012Inventors: David Ranulf Cheshire, Rhona Jane Cox, Premji Meghani, Neal Michael Smith, Jeffrey Paul Stonehouse, Cherylin Francis Preston
-
Publication number: 20120094832Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, are suitable for use as herbicides.Type: ApplicationFiled: August 6, 2008Publication date: April 19, 2012Applicant: SYNGENTA LIMITEDInventors: Melloney Tyte, Christopher John Mathews, Gavin John Hall, William Guy Whittingham, Jeffrey Steven Wailes, James Nicholas Scutt, Stephane André Marie Jeanmart, Russell Viner
-
Publication number: 20120083488Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: June 9, 2010Publication date: April 5, 2012Inventors: Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Nobuya Ishii, Hiroshi Sakamoto, WooSang Hong, MinJeong Park, Yoshiyuki Ono, Yashuharu Kato, Kenji Morikami, Takashi Emura, Nobuhiro Oikawa
-
Publication number: 20120040826Abstract: Bicyclic dione compounds, and derivatives thereof, which are suitable for use as herbicides.Type: ApplicationFiled: July 30, 2008Publication date: February 16, 2012Applicant: SYNGENTA LIMITEDInventors: Stephane André Marie Jeanmart, Christopher John Mathews, John Benjamin Taylor, Steve Smith
-
Patent number: 8114994Abstract: Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.Type: GrantFiled: February 10, 2009Date of Patent: February 14, 2012Assignee: Emory UniversityInventors: Dennis C. Liotta, Shuli Mao, Michael Hager, Raymond F Schinazi
-
Patent number: 8114997Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehyd-ro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.Type: GrantFiled: January 4, 2008Date of Patent: February 14, 2012Assignee: Pharmasset, Inc.Inventors: Michael J. Otto, Junxing Shi, Kyoichi A. Watanabe
-
Publication number: 20120035196Abstract: [Problem] The present invention has an object to provide a compound having a GPR40 agonistic activity, which is useful as a pharmaceutical composition, an insulin secretion promoter, or an agent for preventing/treating diabetes. [Means for Solution] The present inventors have extensively studied a compound having a GPR40 agonistic activity, and as a result, they have found that the compound (I) of the present invention or a pharmaceutically acceptable salt thereof, in which a carboxylic acid is bonded to a bicyclic or tricyclic moiety through methylene, and further, a benzene ring substituted with a monocyclic 6-membered aromatic ring is bonded to a bicyclic or tricyclic moiety through —O-methylene or —NH-methylene, has an excellent GPR40 agonistic activity. They have also found that the compound has an excellent insulin secretion promoting action and strongly inhibits increase in the blood glucose after glucose loading, thereby completing the present invention.Type: ApplicationFiled: April 21, 2010Publication date: February 9, 2012Inventors: Kenji Negoro, Kei Ohnuki, Yasuhiro Yonetoku, Kazuyuki Kuramoto, Yasuharu Urano, Hideyuki Watanabe
-
Publication number: 20120021912Abstract: Compounds of Formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.Type: ApplicationFiled: January 18, 2010Publication date: January 26, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: Christopher John Mathews, John Finney, James Nicholas Scutt, Louisa Robinson, John Stephen Delaney
-
Publication number: 20120021907Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.Type: ApplicationFiled: January 6, 2010Publication date: January 26, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: Christopher John Mathews, John Finney, James Nicholas Scutt, Louisa Robinson, John Stephen Delaney
-
Publication number: 20120022087Abstract: The invention relates to amorphous ambrisentan, preferably together with a surface stabiliser in the form of a stable intermediate. The invention further relates to methods of producing stable amorphous ambrisentan and pharmaceutical formulations containing stable amorphous ambrisentan.Type: ApplicationFiled: August 7, 2009Publication date: January 26, 2012Applicant: Ratiopharm GmbHInventors: Kathrin Rimkus, Frank Muskulus, Sandra Brueck, Jana Paetz
-
Publication number: 20110319439Abstract: MCHR1 antagonists are provided having the following Formula I: wherein all of the variables are defined herein. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.Type: ApplicationFiled: March 9, 2010Publication date: December 29, 2011Inventor: Saleem Ahmad
-
Publication number: 20110263582Abstract: This invention relates to novel compounds of the Formula (I), (Ia) and (Ib), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, j which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell Or the inhibition of the conversion of cortisone to Cortisol in a cell.Type: ApplicationFiled: December 10, 2008Publication date: October 27, 2011Inventors: David A. Claremon, Linghang Zhuang, Colin M. Tice, Yuanjie Ye, Wei He, Suresh B. Singh, Zhenrong Xu, Salvacion Cacatian, Wei Zhao
-
Publication number: 20110263854Abstract: The present invention relates to improved processes for the preparation of Endothelin receptor antagonists, their salts and intermediates.Type: ApplicationFiled: November 4, 2009Publication date: October 27, 2011Inventors: Manne Satyanarayana Reddy, Chakilam Nagaraju, Achampeta Kodanda Ramprasad
-
Publication number: 20110201634Abstract: The present invention relates to a dihydropyrimidinone compound of formula (I) wherein X represents O, S, etc. and R? represents alkyl, alkoxy, thioalkyl, thioalkyloxy, phenyl, substituted phenyl, phenyloxy, substituted phenyloxy, amino, monosubstitutedamino, disubstitutedamino, aryl, heteroaryl, aryloxy, heteroaryloxy, halo; R? represents alkoxy, phenyloxy, substituted phenyloxy, aryloxy, heteroaryloxy, halo, NR1R2 and Rn represents OR1, NH2, SR1, NR1R2; R1, R2=H, alkyl, phenyl, aryl, OCOR3, SCOR3, NHCOR3, NR1COR3; R3 represents alkyl, phenyl, aryl, heteroaryl.Type: ApplicationFiled: June 15, 2009Publication date: August 18, 2011Applicants: DELHI UNIVERSITY, VALLABHBHAI PATEL CHEST INSTITUTEInventors: Virinder Singh Parmar, Hanumanthrao Guru Raj, Ashok Kumar Prasad
-
Publication number: 20110193022Abstract: Provided is a liquid crystal compound having general physical properties necessary for a compound, stability to heat, light or the like, a wide liquid crystal phase temperature range, a high clearing point, an excellent compatibility with other liquid crystal compounds, a large refractive index anisotropy and a large dielectric anisotropy. Provided are a liquid crystal composition including the liquid crystal compound, and a liquid crystal display device containing the liquid crystal composition. The compound is represented by formula (1): wherein, for example, R1 is alkyl having 1 to 20 carbons; at least one of the rings A1 to A6 is pyrimidine-2,5-diyl or pyridine-2,5-diyl and the others are 1,4-cyclohexylene or 1,4-phenylene; Z1 to Z6 are a single bond; L1 to L4 is hydrogen or halogen; X1 is hydrogen, halogen, —C?N or alkyl having 1 to 10 carbons; and l, m, n, o, p and q are 0 or 1 and l+m+n+o+p+q=3.Type: ApplicationFiled: October 14, 2009Publication date: August 11, 2011Applicants: JNC CORPORATION, CHISSO PETROCHEMICAL CORPORATIONInventors: Hiroyuki Tanaka, Kouki Sagou
-
Patent number: 7994318Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.Type: GrantFiled: March 18, 2010Date of Patent: August 9, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
-
Publication number: 20110189243Abstract: The invention relates to pharmaceutical formulations for reducing pulmonary blood pressure containing micronised ambrisentan, preferably in the form of an intermediate together with a hydrophilising agent. The invention also relates to methods of preparing pharmaceutical formulations containing micronised ambrisentan.Type: ApplicationFiled: August 7, 2009Publication date: August 4, 2011Inventors: Katrin Rimkus, Frank Muskulus, Sandra Brueck, Jana Paetz, Dunja Kotschenreuther
-
Publication number: 20110160455Abstract: A 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound of the formula (3): [R is a hydrocarbyl group], is prepared by the steps of: (I) reacting an isobutyrylacetate ester with 4-fluorobenzaldehyde and urea in the presence of a protonic compound and a metal salt; (II) oxidizing the reaction product of the step (I); (III) reacting the oxidation product of the step (II) with an organic sulfonyl halide or an organic sulfonyl anhydride; and (IV) reacting the reaction product of the step (III) with N-methyl-N-methanesulfonamide.Type: ApplicationFiled: September 23, 2010Publication date: June 30, 2011Applicant: AstraZeneca UK Ltd.Inventors: Akio Matsushita, Mizuho Oda, Yasuhiro Kawachi, Jun-ichi Chika
-
Publication number: 20110152301Abstract: The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV.Type: ApplicationFiled: December 22, 2010Publication date: June 23, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: David Rekosh, Marie-Louise Hammarskjöld
-
Publication number: 20110124651Abstract: There is provided a fluorine-containing organosulfur compound having an excellent control effect on harmful arthropods, which is represented by the formula (I): wherein m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 6-membered aromatic heterocyclic group; R1 to R4 are the same or different and represent a hydrogen atom, a C1-C4 chain hydrocarbon group optionally substituted with a halogen atom, etc.; and Q represents a C1-C5 haloalkyl group containing at least one fluorine atom, or a fluorine atom.Type: ApplicationFiled: August 22, 2008Publication date: May 26, 2011Inventors: Koji Kumamoto, Hiroyuki Miyazaki
-
Patent number: 7939660Abstract: A novel process for preparing emtricitabine, and more particularly a process for preparing emtricitabine involving the formation and isolation of intermediate compounds in salified form, is described.Type: GrantFiled: April 6, 2009Date of Patent: May 10, 2011Assignee: Archimica S.r.l.Inventors: Giorgio Bertolini, Maurizio Deleo, Marco Frigerio, Massimo Losa, Maurizio Velati
-
Patent number: RE42462Abstract: Carboxylic acid derivatives where R-R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.Type: GrantFiled: October 7, 1995Date of Patent: June 14, 2011Assignee: Abbott GmbH & Co. KGInventors: Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Muller, Ernst Baumann, Joachim Rheinheimer, Uwe Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, Manfred Raschack
-
Patent number: RE42477Abstract: Carboxylic acid derivatives where R-R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.Type: GrantFiled: March 27, 1997Date of Patent: June 21, 2011Assignee: Abbott GmbH & Co. KGInventors: Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Muller, Ernst Baumann, Joachim Rheinheimer, Uwe Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, Manfred Raschack
-
Patent number: RE43748Abstract: Nitrogen-containing heterocyclic carboxamide derivatives represented by the following general formula: wherein ring A is a substituted or unsubstituted pyrazine, pyrimidine, pyridazine or triazine ring; R1 is O or OH; R2 is a hydrogen atom, an acyl group or a substituted or unsubstituted carbamoylalkyl or carboxyalkyl group; and the broken line represents a single bond or a double bond; or salts thereof are useful for preventing and treating virus infections and especially influenza virus infections.Type: GrantFiled: August 26, 2010Date of Patent: October 16, 2012Assignee: Toyama Chemical Co., Ltd.Inventors: Yousuke Furuta, Hiroyuki Egawa, Nobuhiko Nomura